Sheena Jonathan, who serves as a director and co-founder of Natera, Inc. (NASDAQ:NTRA), disclosed a sale of company stock earlier this month while also recording a recent equity award, according to an SEC Form 4 filing.
The filing shows Jonathan sold 127 shares of Natera common stock on March 10, 2026, at a per-share price of $204.1327, producing a gross transaction amount of $25,924. Market quotations at the time of reporting show Natera trading at $196.61 and carrying a market capitalization of $27.88 billion.
One day prior to the sale, on March 9, 2026, Jonathan received 258 shares via the issuance of fully-vested Restricted Stock Units, also recorded in the Form 4. After accounting for these transactions, Jonathan's direct ownership position in Natera stands at 262,325 shares.
In addition to her direct holdings, the filing indicates Jonathan has indirect stakes through trusts: 21,782 shares held by Caraluna 1 Trust and 21,782 shares held by Caraluna 2 Trust.
Natera's recent operating results and analyst commentary provide context for the timing of the transactions. For the fourth quarter of 2025, the company reported revenue of $666 million, exceeding the consensus expectation of $590.72 million, a 12.66% positive surprise. The quarterly performance reflected significant year-over-year growth and was supported by higher test volumes across Natera's business segments, with particular expansion in clinical test volume for Signatera.
Market commentators and research providers remain varied in their assessments. Analysts' price targets cited in public materials span a range from $190 to $300. Canaccord Genuity reiterated a Buy rating and maintained a $285 price target, while Morgan Stanley lowered its target to $250 from $265 but retained an Overweight rating.
Independent analysis available through InvestingPro highlights the company's strong revenue trend - reporting 35.9% revenue growth over the last twelve months - while also indicating that Natera appears overvalued at current market levels. InvestingPro offers a deeper Pro Research Report for subscribers seeking further detail.
The SEC filing and the reported financial results together create a detailed snapshot of insider activity and company performance, while leaving open the customary limitations of public filings - they document the transactions and holdings but do not explain the personal motives for the sale.
Readers should note the factual record described above: the exact share counts, transaction prices, ownership totals, quarterly revenue and analyst target actions are those reported in regulatory filings and company disclosures.